Denver, Colorado: Mirada Medical software applied to state-of-the-art Adaptive Radiotherapy (ART) is the subject of an oral presentation at the annual conference of the American Society for Radiation Oncology (ASTRO). The ASTRO conference is September 14-17 in San Francisco, California and is attended by leading radiation oncology professionals from around the world.

A critical yet hugely time-consuming step in ART is the monitoring of patients throughout the course of therapy to determine which need to be replanned. This need presents a significant barrier to adoption of ART methods in the clinic. The original research, being presented by collaborators from the University Medical Center, Groningen, The Netherlands, (230, Wednesday 17, 11:15am, Room 103), examined the possibility of using advanced image registration methods to automate patient monitoring and to flag only those patients that might need further investigation. Such a method can create a significant time savings.

The study included twenty-eight locally advanced Head and Neck Cancer patients treated with IMRT. For each patient, the planning target volumes and organs at risk were contoured on the planning CT and propagated to a rescan using deformable image registration (Mirada RTx). Dose distributions of the treatment plan were calculated on both images. Replanning decisions are usually made by applying constraints to the recalculated dose on the rescan, using the warped structures. However, as a surrogate for recalculation, a dose projection method using a rigid translation applied to the original dose mapped onto the rescan was used. The same set of constraints were then applied to this resulting dose, in order to decide whether a replan was required. The results showed that the automated dose projection method correctly removed 90% of cases from further evaluation while identifying 100% of those that required investigation. This indicates rigid dose projection onto rescan CTs is a fast and automated substitute for dose recalculation since full recalculation and replanning decisions need only be made on those patients flagged by the system.

The study forms part of Mirada's Registration AssuranceSM program, a comprehensive program for ensuring DIR quality and continuous improvement through rigorous scientific validation of technology, education, comprehensive QC tools and a commitment to ongoing development and support. Mirada recognizes the need for ongoing innovation in workflows such as adaptive replanning for RT, as well as assurance that their technology can be trusted to provide quality of care to the patient. The registration, contouring and adaptive replanning workflows used in the study are all available in the new releases of Mirada RTx and Mirada Workflow Box.

"Adaptive Radiotherapy presents an exciting opportunity for clinics to move to the next stage of personalized treatment," stated Dr. Timor Kadir, Chief Technology Officer of Mirada Medical. "Mirada is committed to applying its advanced deformable registration and imaging technology for making Adaptive Radiotherapy practical for every clinic and every patient."

Mirada Medical will be demonstrating its complete suite of radiotherapy applications, and highlighting its unique Registration AssuranceSM program at ASTRO, booth #308. The researchers will be available to discuss their research and answer questions.

For more information, please contact:

Mirada Medical

US/Worldwide: Robert Ripley

tel: (440) 591-8638

Insource Communications

rripley@insourceinc.com

enquiries@mirada-medical.com

www.mirada-medical.com

U.S. Headquarters:

Mirada Medical USA, Inc.

999 18th Street

Suite 2025N

Denver, CO 80202

Tel: (303) 379-9228

World Headquarters:

Oxford Centre for Innovation

New Road, Oxford

OX1 1BY

United Kingdom

Tel: +44(0)1865 261410

About Mirada Medical Ltd

Mirada Medical is a prominent global brand in medical imaging software. Mirada's innovative software solutions are routinely used in radiology, molecular imaging, radiation oncology and in multidisciplinary meetings throughout hospitals, imaging centers and cancer centers worldwide. Mirada excels at combining scientifically advanced technology with practical application for diagnosis, management and treatment of cancer and other diseases.

Mirada products are available directly from the company, and also through a broad network of well-known healthcare companies such as Varian, GE, McKesson, Siemens, Vital Images and select others. Mirada was originally founded in 2001 by medical imaging researchers at Oxford University. The company's world headquarters remains in Oxford, England and continues to attract preeminent talent in science and engineering.

Mirada Medical, RTx, Casemeeting, Caseaccess and XD3 are all trademarks of Mirada Medical Ltd.